Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
2
×
boston blog main
clinical trials
life sciences
national blog main
new york blog main
alirocumab
alnylam pharmaceuticals
amgen
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
boston
boston top stories
drugs
duchenne muscular dystrophy
dyne therapeutics
evercore isi
evolocumab
facioscapulohumeral muscular dystrophy
gene therapy
heart attack
inclisiran
joseph swartz
joshua brumm
kaleido biosciences
medicines co.
muscular dystrophy
myotonic dystrophy type 1
national top stories
new york
new york top stories
pcsk9 inhibitors
rare disease drugs
regeneron pharmaceuticals
rna interference
romesh subramanian
san diego blog main
What
data
2
×
drug
long
2
×
medicines
ago
alnylam
based
biotechs
cholesterol
considering
diseases
dyne
early
evidence
expected
experimental
eyes
genetic
having
heart
humans
ipo
ipos
lasting
looms
lowering
medco
muscle
new
partner
pharmaceuticals
presented
rare
reach
reckoning
rna
supporting
term
therapeutics
touts
Language
unset
Current search:
long
×
biotech
×
data
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
